Wt1 substitution pepides
    1.
    发明申请
    Wt1 substitution pepides 有权
    Wt1替代pepides

    公开(公告)号:US20060205667A1

    公开(公告)日:2006-09-14

    申请号:US10528360

    申请日:2003-09-19

    IPC分类号: A61K38/10 C07K7/08

    CPC分类号: C07K14/47

    摘要: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X—Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.

    摘要翻译: 提供WT1的新型取代型肽,其中半胱氨酸残基被定义的氨基酸残基取代,编码所述肽的多核苷酸,在体内或体外使用那些肽或多核苷酸的癌症疫苗等。 包含下式的氨基酸序列的肽:XY-Thr-Trp-Asn-Gln-Met-Asn-Leu(SEQ ID NO:4),其中X表示Ser,Ala,Abu,Arg,Lys,Orn,Cit, Leu,Phe或Asn,Y表示Tyr或Met,并且其具有诱导CTL的活性,编码所述肽的多核苷酸,包含那些肽或多核苷酸作为活性成分的癌症疫苗等。

    WT1 substitution peptides
    2.
    发明授权
    WT1 substitution peptides 有权
    WT1取代肽

    公开(公告)号:US07378384B2

    公开(公告)日:2008-05-27

    申请号:US10528360

    申请日:2003-09-19

    IPC分类号: A61K38/02 A61K38/08

    CPC分类号: C07K14/47

    摘要: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided.Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.

    摘要翻译: 提供WT1的新型取代型肽,其中半胱氨酸残基被定义的氨基酸残基取代,编码所述肽的多核苷酸,在体内或体外使用那些肽或多核苷酸的癌症疫苗等。 包含下式的氨基酸序列的肽:XY-Thr-Trp-Asn-Gln-Met-Asn-Leu(SEQ ID NO:4),其中X表示Ser,Ala,Abu,Arg,Lys,Orn,Cit, Leu,Phe或Asn,Y表示Tyr或Met,并且其具有诱导CTL的活性,编码所述肽的多核苷酸,包含那些肽或多核苷酸作为活性成分的癌症疫苗等。

    Peg-modified HGF
    3.
    发明授权
    Peg-modified HGF 失效
    Peg修饰的HGF

    公开(公告)号:US5977310A

    公开(公告)日:1999-11-02

    申请号:US913236

    申请日:1997-11-04

    摘要: This invention relates to a PEG-modified HGF (Hepatocyte Growth Factor), namely HGF modified by polyethylene glycol. The PEG-modified HGF of the invention has a prolonged clearance in vivo, effectively exhibits its physiological activity for a long period of time, and has the same physiological activity as HGF, which makes it possible to reduce the dose and relieve the side effects of the same.

    摘要翻译: PCT No.PCT / JP96 / 00599 Sec。 371日期1997年11月4日 102(e)日期1997年11月4日PCT 1996年3月7日PCT公布。 出版物WO96 / 28475 日本1996年9月19日本发明涉及PEG修饰的HGF(肝细胞生长因子),即由聚乙二醇改性的HGF。 本发明的PEG修饰的HGF在体内具有延长的清除率,长时间有效地显示其生理活性,并且具有与HGF相同的生理活性,这使得可以减少剂量并减轻副作用 一样。